🔎 Trials Near Me

Utama › Kanser Ginjal (Karsinoma Sel Renal) › Washington

Kajian klinikal Kanser Ginjal (Karsinoma Sel Renal) di Washington

12 kajian untuk Kanser Ginjal (Karsinoma Sel Renal) sedang mencari peserta di lokasi di Washington.

Bandar di Washington

Teks kajian rasmi (Bahasa Inggeris)

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

  • Swedish Medical Center, Seattle
  • Fred Hutchinson Cancer Center, Seattle
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06234605

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Providence Regional Cancer System-Aberdeen, Aberdeen
  • PeaceHealth Saint Joseph Medical Center, Bellingham
  • Providence Regional Cancer System-Centralia, Centralia
  • dan 19 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • Valley Medical Center, Renton
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT03866382

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

  • Fred Hutchinson Cancer Center, Seattle
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT04981119

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

  • Northwest Medical Specialties, Tacoma
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06047379

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

  • Local Institution - 0095, Seattle
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07293351

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

  • Virginia Mason Medical Center, Seattle
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT05327686

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  • Fred Hutchinson Cancer Center, Seattle
  • University Of Washington Medical Center, Seattle
  • Northwest Cancer Specialists, P.C., Vancouver
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07227415

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

  • Xencor Investigative Site, Seattle
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Ogo 2026 · NCT05433142

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

  • Fred Hutch Cancer Center, Seattle
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2025 · NCT06682793

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

  • Valley Medical Center, Renton
  • North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2025 · NCT04510597

A Study of IBI363 in Subjects with Advanced Solid Malignancies

  • Fred Hutchinson Cancer Center, Seattle
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Dis 2024 · NCT06281678

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.